Mumbai, June 10: HAB Pharmaceuticals & Research Limited has announced an ambitious growth roadmap following the successful completion of its strategic merger with Signature Phytochemical Industries. The merger, finalized in March 2026 through a slump sale transaction, brings both businesses under a single consolidated entity with an estimated turnover of approximately ₹600 crore.
The consolidation is aimed at streamlining operations, enhancing governance structures, and creating a stronger foundation for long-term growth. Leveraging expanded manufacturing capabilities, strengthened research and development, and a growing focus on specialty pharmaceutical products, the company has set a target of achieving revenues between ₹2,500 crore and ₹3,000 crore by 2030.
Strengthening Manufacturing and R&D Capabilities
The merger significantly enhances HAB Pharmaceuticals' manufacturing and research ecosystem. The combined entity plans to focus on off-patent molecules and complex dosage forms across high-growth therapeutic segments including oncology, autoimmune disorders, chronic diseases, and rare disease treatments.
By integrating Signature Phytochemical Industries' expertise in oral formulations such as tablets, capsules, and creams, HAB Pharmaceuticals aims to expand its product portfolio while driving operational efficiencies across its manufacturing network.
New Manufacturing Facilities to Drive Growth
As part of its expansion strategy, HAB Pharmaceuticals is commissioning two advanced manufacturing facilities scheduled to commence commercial production by August 2026.
The first facility is a sterile manufacturing plant designed for the production of semaglutide, prefilled syringes, injectables, vials, and lyophilized formulations. The second is a fully automated closed-loop Oral Solid Dosage (OSD) facility that will significantly enhance production efficiency, quality control, and scalability.
These investments are expected to strengthen the company's ability to meet increasing domestic and international demand while supporting future regulatory approvals.
Expanding Global Footprint
HAB Pharmaceuticals is also accelerating its international growth strategy, with key focus markets including Latin America, Central Asia, Southeast Asia, and Africa.
The company believes its expanded manufacturing footprint and broader product capabilities will enable it to capitalize on growing opportunities across emerging pharmaceutical markets. Regulatory audits have already been conducted in countries such as Uganda, Tanzania, and Iraq, laying the groundwork for deeper market penetration.
Positioned for the Next Phase of Growth
Founded in 1991, HAB Pharmaceuticals has established a strong presence across multiple therapeutic categories including antibiotics, cardiovascular medicines, and non-steroidal anti-inflammatory drugs (NSAIDs). The merger marks a significant milestone in the company's evolution, creating a more integrated pharmaceutical platform capable of supporting future expansion initiatives.
With a consolidated turnover of approximately ₹600 crore and a clear vision to reach ₹3,000 crore in revenue by 2030, HAB Pharmaceuticals is positioning itself for its next phase of growth through operational integration, specialty drug development, advanced manufacturing, and global market expansion.
